Falhammar H, Thorén M, Hagenfeldt K
Department of Endocrinology, Metabolism and Diabetes, Karolinska University Hospital and Karolinska Institute, Stockholm, Sweden.
J Endocrinol Invest. 2008 Feb;31(2):176-80. doi: 10.1007/BF03345586.
A 31-yr-old woman presenting with a history of hirsutism, amenorrhea, and infertility was previously assumed to have polycystic ovary syndrome. A new gynecological-endocrine evaluation demonstrated elevated testosterone/SHBG ratio, serum 17-hydroxyprogesterone (17-OHP), and urinary pregnantriol. She was diagnosed with non-classic congenital adrenal hyperplasia. In spite of treatment with dexamethasone and fludrocortisone in doses that suppressed adrenal androgens and 17-OHP into normal range or below, she did not ovulate. Clomiphene citrate and then FSH/hCG treatment in several cycles gave no consistent ovulation. Progesterone levels remained elevated throughout the cycles indicating a possible contribution from the adrenals. Oral glucose tolerance was normal, but the homeostasis model assessment index indicated insulin resistance. With metformin 1500 mg daily the index decreased remarkably from 2.77 to 0.96 with a few ovulations but no pregnancy occurred. Three cycles of IVF treatment thereafter were unsuccessful. Three months after the last in vitro fertilization (IVF) cycle, still on dexamethasone, fludrocortisone, and metformin, her menstruations became regular and she thereafter became pregnant. During pregnancy metformin was discontinued and dexamethasone replaced with prednisolone. Mild gestational diabetes developed and insulin was given. A healthy boy was born at term by elective Cesarean section. A CYP21- gene analysis had not indicated any of the known mutations but after gene sequencing a novel mutation was found, namely R233G. This case confirms the necessity of adding an analysis of 17-OHP when evaluating women with hirsutism and menstrual disturbances and if an elevated value is found, the advantage of performing a mutation analysis to facilitate counseling and decisions on treatment.
一名31岁女性,有多毛、闭经和不孕史,此前被诊断为多囊卵巢综合征。一项新的妇科内分泌评估显示,睾酮/性激素结合球蛋白(SHBG)比值、血清17-羟孕酮(17-OHP)和尿孕三醇升高。她被诊断为非经典型先天性肾上腺皮质增生症。尽管使用地塞米松和氟氢可的松治疗,将肾上腺雄激素和17-OHP抑制到正常范围或以下,但她仍未排卵。在几个周期中使用枸橼酸氯米芬,然后使用促卵泡生成素/人绒毛膜促性腺激素(FSH/hCG)治疗,均未出现持续排卵。整个周期中孕酮水平持续升高,提示肾上腺可能有一定作用。口服葡萄糖耐量正常,但稳态模型评估指数提示存在胰岛素抵抗。每日服用1500毫克二甲双胍后,该指数从2.77显著降至0.96,有几次排卵,但未怀孕。此后三个周期的体外受精(IVF)治疗均未成功。最后一次IVF周期结束三个月后,她仍在服用地塞米松、氟氢可的松和二甲双胍,月经变得规律,随后怀孕。孕期停用二甲双胍,地塞米松换成泼尼松龙。出现轻度妊娠期糖尿病,给予胰岛素治疗。足月时通过择期剖宫产分娩出一个健康男婴。CYP21基因分析未显示任何已知突变,但基因测序后发现了一个新突变,即R233G。该病例证实,在评估有多毛和月经紊乱的女性时,有必要增加17-OHP分析;如果发现该值升高,进行突变分析有助于咨询和治疗决策。